URGN logo

UroGen Pharma Ltd. (URGN) EBITDA

annual EBITDA:

-$110.33M-$28.43M(-34.71%)
December 31, 2024

Summary

  • As of today (September 16, 2025), URGN annual EBITDA is -$110.33 million, with the most recent change of -$28.43 million (-34.71%) on December 31, 2024.
  • During the last 3 years, URGN annual EBITDA has fallen by -$2.74 million (-2.54%).
  • URGN annual EBITDA is now -11013.45% below its all-time high of $1.01 million, reached on December 31, 2016.

Performance

URGN EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherURGNincome statement metrics

quarterly EBITDA:

-$40.85M-$4.43M(-12.18%)
June 30, 2025

Summary

  • As of today (September 16, 2025), URGN quarterly EBITDA is -$40.85 million, with the most recent change of -$4.43 million (-12.18%) on June 30, 2025.
  • Over the past year, URGN quarterly EBITDA has dropped by -$15.28 million (-59.73%).
  • URGN quarterly EBITDA is now -392.18% below its all-time high of $13.98 million, reached on December 31, 2016.

Performance

URGN quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherURGNincome statement metrics

TTM EBITDA:

-$121.90M-$15.28M(-14.33%)
June 30, 2025

Summary

  • As of today (September 16, 2025), URGN TTM EBITDA is -$121.90 million, with the most recent change of -$15.28 million (-14.33%) on June 30, 2025.
  • Over the past year, URGN TTM EBITDA has dropped by -$43.66 million (-55.81%).
  • URGN TTM EBITDA is now -2766.23% below its all-time high of $4.57 million, reached on December 31, 2016.

Performance

URGN TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherURGNincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

URGN EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-34.7%-59.7%-55.8%
3 y3 years-2.5%-124.0%-48.3%
5 y5 years+11.5%-30.4%+7.8%

URGN EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-34.7%at low-212.2%at low-91.0%at low
5 y5-year-43.7%+11.5%-212.2%at low-91.0%+11.3%
alltimeall time<-9999.0%+11.5%-392.2%at low-2766.2%+11.3%

URGN EBITDA History

DateAnnualQuarterlyTTM
Jun 2025
-
-$40.85M(+12.2%)
-$121.90M(+14.3%)
Mar 2025
-
-$36.42M(+33.1%)
-$106.62M(+11.5%)
Dec 2024
-$110.33M(+34.7%)
-$27.35M(+58.3%)
-$95.60M(+16.0%)
Sep 2024
-
-$17.28M(-32.4%)
-$82.43M(+5.4%)
Jun 2024
-
-$25.58M(+0.7%)
-$78.23M(+15.7%)
Mar 2024
-
-$25.39M(+79.0%)
-$67.61M(+5.9%)
Dec 2023
-$81.90M(-16.2%)
-$14.19M(+8.4%)
-$63.83M(-8.1%)
Sep 2023
-
-$13.09M(-12.5%)
-$69.48M(-6.2%)
Jun 2023
-
-$14.95M(-30.8%)
-$74.05M(-4.3%)
Mar 2023
-
-$21.61M(+9.0%)
-$77.33M(+0.1%)
Dec 2022
-$97.77M(-9.1%)
-$19.83M(+12.3%)
-$77.22M(+0.5%)
Sep 2022
-
-$17.65M(-3.2%)
-$76.86M(-6.5%)
Jun 2022
-
-$18.24M(-15.2%)
-$82.19M(-4.8%)
Mar 2022
-
-$21.50M(+10.5%)
-$86.33M(-4.6%)
Dec 2021
-$107.60M(-13.7%)
-$19.46M(-15.3%)
-$90.52M(-7.3%)
Sep 2021
-
-$22.99M(+2.7%)
-$97.69M(-5.5%)
Jun 2021
-
-$22.38M(-12.9%)
-$103.33M(-8.0%)
Mar 2021
-
-$25.69M(-3.6%)
-$112.28M(-10.0%)
Dec 2020
-$124.69M
-$26.64M(-6.9%)
-$124.69M(-9.3%)
DateAnnualQuarterlyTTM
Sep 2020
-
-$28.63M(-8.6%)
-$137.50M(+4.0%)
Jun 2020
-
-$31.32M(-17.8%)
-$132.26M(+6.1%)
Mar 2020
-
-$38.10M(-3.4%)
-$124.63M(+14.5%)
Dec 2019
-
-$39.44M(+68.6%)
-$108.89M(+16.6%)
Sep 2019
-
-$23.39M(-1.3%)
-$93.42M(+2.6%)
Jun 2019
-
-$23.69M(+5.9%)
-$91.06M(+6.2%)
Mar 2019
-
-$22.37M(-6.7%)
-$85.75M(+11.4%)
Dec 2018
-$76.76M(+288.8%)
-$23.97M(+14.0%)
-$76.96M(+22.0%)
Sep 2018
-
-$21.03M(+14.4%)
-$63.10M(+49.0%)
Jun 2018
-
-$18.38M(+35.3%)
-$42.35M(+42.0%)
Mar 2018
-
-$13.58M(+34.5%)
-$29.83M(+51.1%)
Dec 2017
-$19.74M(-2052.8%)
-$10.10M(+3431.5%)
-$19.74M(-555.0%)
Sep 2017
-
-$286.00K(-95.1%)
$4.34M(-403.9%)
Jun 2017
-
-$5.86M(+67.9%)
-$1.43M(-232.3%)
Mar 2017
-
-$3.49M(-125.0%)
$1.08M(-76.4%)
Dec 2016
$1.01M(-108.2%)
$13.98M(-331.0%)
$4.57M(-148.6%)
Sep 2016
-
-$6.05M(+80.3%)
-$9.41M(+180.3%)
Jun 2016
-
-$3.36M
-$3.36M
Dec 2015
-$12.30M
-
-

FAQ

  • What is UroGen Pharma Ltd. annual EBITDA?
  • What is the all time high annual EBITDA for UroGen Pharma Ltd.?
  • What is UroGen Pharma Ltd. annual EBITDA year-on-year change?
  • What is UroGen Pharma Ltd. quarterly EBITDA?
  • What is the all time high quarterly EBITDA for UroGen Pharma Ltd.?
  • What is UroGen Pharma Ltd. quarterly EBITDA year-on-year change?
  • What is UroGen Pharma Ltd. TTM EBITDA?
  • What is the all time high TTM EBITDA for UroGen Pharma Ltd.?
  • What is UroGen Pharma Ltd. TTM EBITDA year-on-year change?

What is UroGen Pharma Ltd. annual EBITDA?

The current annual EBITDA of URGN is -$110.33M

What is the all time high annual EBITDA for UroGen Pharma Ltd.?

UroGen Pharma Ltd. all-time high annual EBITDA is $1.01M

What is UroGen Pharma Ltd. annual EBITDA year-on-year change?

Over the past year, URGN annual EBITDA has changed by -$28.43M (-34.71%)

What is UroGen Pharma Ltd. quarterly EBITDA?

The current quarterly EBITDA of URGN is -$40.85M

What is the all time high quarterly EBITDA for UroGen Pharma Ltd.?

UroGen Pharma Ltd. all-time high quarterly EBITDA is $13.98M

What is UroGen Pharma Ltd. quarterly EBITDA year-on-year change?

Over the past year, URGN quarterly EBITDA has changed by -$15.28M (-59.73%)

What is UroGen Pharma Ltd. TTM EBITDA?

The current TTM EBITDA of URGN is -$121.90M

What is the all time high TTM EBITDA for UroGen Pharma Ltd.?

UroGen Pharma Ltd. all-time high TTM EBITDA is $4.57M

What is UroGen Pharma Ltd. TTM EBITDA year-on-year change?

Over the past year, URGN TTM EBITDA has changed by -$43.66M (-55.81%)
On this page